TLSA tizianalifesciences.com: יחס שווי שוק לשווי בספרים

The valuation foundation of Tiziana Life Sciences (TLSA) is based on patents in the field of nasal antibody administration to combat neuroimmune pathology, which is confirmed by the share price retrospective at the level of -44.80. The business relies on the creation of monoclonal drugs with minimal costs during mass production. The operating model utilizes GMP contractors for batch synthesis, ensuring strict adherence to production schedules and the absence of disruptions.

Holding patents for a unique antibody delivery system, Tiziana Life Sciences (TLSA) claims pricing power, which is reflected in the market value premium over net assets. This indicator measures the gap between the exchange valuation and the book value of capital; therefore, the current market-to-book value ratio demonstrates market expectations regarding the future capitalization of the company's intellectual property.